Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial - Winer, Eric P; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Muñoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; et al. (The lancet oncology, 2021)
Keywords: Adolescent; Adult; Adverse events; Aged; Anthracycline; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - genetics; Breast cancer; Cancer; Cancer therapies; Chemotherapy; Clinical trials; Drug dosages; Female; Gemcitabine; Hematology, Oncology, and Palliative Medicine; Humans; Immunotherapy; Intravenous administration; Leukocytes (neutrophilic); Life Sciences; Medical treatment; Metastases; Metastasis; Middle Aged; Monoclonal antibodies; Neoplasm Metastasis; Neutropenia; Pancytopenia; Patients; PD-L1 protein; Pembrolizumab; Progression-Free Survival; Response rates; Sepsis; Targeted cancer therapy; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology; Tumors; Vinorelbine; Young Adult